EcoDrugPlus

Sodium Voltage-Gated Channel Alpha Subunit 1

Ensembl ID : ENSPCTG00005001609
Gene Symbol: SCN1A
4 Cross references
139 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 10

Ensembl ID : ENSPCTG00005014713
Gene Symbol: SCN10A
3 Cross references
297 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 11

Ensembl ID : ENSPCTG00005016043
Gene Symbol: SCN11A
1 Cross references
96 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 2

Ensembl ID : ENSPCTG00005001088
Gene Symbol: SCN2A
4 Cross references
130 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 3

Ensembl ID : ENSPCTG00005000619
Gene Symbol: SCN3A
4 Cross references
167 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 4

Ensembl ID : ENSPCTG00005017609
Gene Symbol: SCN4A
3 Cross references
193 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 5

Ensembl ID : ENSPCTG00005011952
Gene Symbol: SCN5A
1 Cross references
94 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 7

Ensembl ID : ENSPCTG00005002784
Gene Symbol: SCN7A
1 Cross references
86 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 8

Ensembl ID : ENSPCTG00005015636
Gene Symbol: SCN8A
1 Cross references
274 Possible Orthologues:

Solute Carrier Family 10 Member 2

Ensembl ID : ENSPCTG00005018366
Gene Symbol: SLC10A2
1 Cross references
214 Possible Orthologues:

Solute Carrier Family 22 Member 6

Ensembl ID : ENSPCTG00005009975
Gene Symbol: SLC22A6
3 Cross references
490 Possible Orthologues:

Solute Carrier Family 5 Member 1

Ensembl ID : ENSPCTG00005020215
Gene Symbol: SLC5A1
3 Cross references
250 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).